One of the reasons biotech stocks can be your portfolio’s biggest winners is because of the massive profits companies see after releasing a blockbuster drug – especially with the exorbitantly high prices of this year’s new treatments.
- Three of the Best Biotech Penny Stocks to Buy Now
- The Clear Map to This "Hidden" Investment Treasure
- Biogen Idec (Nasdaq: BIIB) Stock Gains on FDA Approval of New MS Drug
- How to Tap Big Profits in That "Other" Bioscience Niche
- One Stock, 18 Ways to Make Big Money
- Furiex Pharmaceuticals (Nasdaq: FURX) Stock Up 130% Today on This "Blockbuster Drug" News
- Why Chelsea Therapeutics (Nasdaq: CHTP) Stock Is on Fire
- Why Intercept Pharma (Nasdaq: ICPT) Stock Gained 280% Today
- These Five Biotech Firms Will Literally Change the World
- 5 Ways to Spot the Next Hot Biotech Stock
- Biotech Investing: Phase II is the Sweet Spot
Since April 11, Gilead Sciences (Nasdaq: GILD) has scored peak gains of a 74.2% - or more than 175% annualized gains.
Some investors don't want to risk it all during a sell-off - but they still want to take advantage of the growth biotech stocks offer.
For investors looking for the best penny stocks to buy, the biotech sector offers some of the best investment opportunities on the market.
Despite the fact that biotech stocks have been up and down in 2014, Money Morning's Bioscience Investment Specialist Ernie Tremblay sees great profit opportunities for the rest of 2014.
Ask any bioscience researcher about leading trends in medical science, and at some point, you're likely to hear a lot of enthusiasm around the phrase personalized medicine.
That's treatment based on the individual's particular disease state, risk factors, and most importantly, genetic profile. And it's already yielding unheard-of profits for traders and investors.
As scientists reach the discovery limits of "one-size-fits-all" drugs and the ailments that respond to them, such as infections and circulatory diseases, they find themselves up against tougher, wilier, more intractable challenges... Full Story
Biogen Idec Inc. (Nasdaq: BIIB) stock was up 1.6% this morning following news that the company's multiple sclerosis (MS) drug Plegridy was approved by the U.S. Food and Drug Administration on Friday.
The stock is up 14% in the last month and is still showing bullish signs.
At first glance, it may seem like bioscience investing is so complicated and risky that it's hardly worth your time and money to invest, at least if you don't have someone knowledgeable to guide you.
And it's true. Putting your money behind new, experimental drugs, without some guidance, is a crapshoot.
But there's an approach to making profits from this sector that doesn't rely on breakthrough discoveries, expensive drug trials, or constant cash infusions through dilutive public offerings to fuel its engine.
That's what makes the company we'll look at today such an attractive investment.
Welcome to the lucrative world of generics...
To be worth an investor's money, any promising pre-profit biotech needs to offer high scores on three fundamental benchmarks: pipeline depth, lead product quality, and cash-reserve to burn ratio.
Very few young pharma firms meet these qualifications, of course.
That's what makes a company like this so exciting... Full Story
While gains were modest across the three major benchmarks today (Tuesday), there was nothing modest about these major gains for Furiex Pharmaceuticals (Nasdaq: FURX) stock.
Shares of Furiex more than doubled in value, surging some 150% intraday. The closed up 129.91% at $105.69. The reason: The company announced that its experimental drug eluxadoline significantly alleviated diarrhea and abdominal pain, which typically accompany irritable bowel syndrome (IBS), in two large late-stage trials.
Biotech has been the hot sector of late. Last week it was Intercept Pharma shooting up 280% in one day. This week it was a 92% gain for Chelsea Therapeutics. As more development-stage biotechs near approval for new treatments,
Yes, you're reading this correctly - Intercept Pharmaceuticals Inc. (Nasdaq: ICPT) stock more than tripled today (Thursday).
ICPT shares surged 300% in trading today after an analysis by an independent safety committee showed its liver disease drug met the main goal of a mid-stage trial. ICPT stock closed at $275.49, up 280.56% from Wednesday's closing price of $72.39. The stock climbed as high as $305 in intraday trading.
It will help us cure cancer, rid us of the scourge of Alzheimer's, and make 100-year life spans routine. Not only that, but we will lead much healthier and more intelligent lives as a result.
I've followed this field for more than 20 years and have never seen so many advances coming so quickly.
Of course, a big part of that stems from the fact that we have passed the tipping point in other forms of cutting-edge tech the biosciences have adopted -- faster computers, better sensors and tiny digital circuits.
And now that we have a complete map of the human genome, biotech has reached critical mass. Add it all up and you have an unending series of advances that will redefine life in the Era of Radical Change.
To help make sense of the profound impact this will have on our lives, I have compiled a list of five firms that are pushing biotech into new realms.
Each has accomplished a major breakthrough. Take a look...
Biotech Firm No. 1: Spinal Cord TherapyTalk about a brilliant breakthrough. InVivo Therapeutics Holdings Corp. (OTC:NVIV) has a radical new way of treating spinal cord injuries (SCIs).
And it's moving fast. The firm expects to get FDA clearance to begin human trials later this year.
But here is what you need to know about biotech stocks: none of them are created equal.
For all their potential, bio tech stocks remain among the most challenging for investors like you to identify, select and earn money on.
However, with a little bit of the right guidance you can narrow your list to the stocks with the highest likely upside.
In fact, I've developed a five- point checklist of what I look at when screening biotech stocks that I'd like to share with you.
It may not be a road map. The biotech sector just isn't that easy and "x" almost never marks the spot.
But it is a great place to start if you are serious about separating the pretenders from the contenders.
Five Steps for Successful Biotech Stock Investors
As you begin to break down a potential stock consider the following as it relates to your decision.
1) Choose your niche.Biotech is a big term and an even bigger sector. There are literally thousands of companies trying to make their move in everything from vaccines to nano-technology.
There's quite literally no way you can know everything, so stick to the parts of the sector you believe have the biggest potential.
For instance, I think some of the biggest innovations and profits will come from bio tech companies that link living systems with their digital counterparts.
So I tend to concentrate my biotech investments in companies that are exploring synthetic biology and computational bioinformatics.
To me it's a no brainer.
While there is no question that traditional bio tech will be big, over the next few years we will see the line blur very rapidly between what we need to live and how we actually live - aided by technology.
Admittedly, I have a rather selfish reason...
Obviously, I accepted.
Phase II trials are my favorite time to get involved in a biotech company. I'll explain why in a moment. But first, a quick review of the phases of clinical trials...